A Phase 4 interventional study of Tolvaptan and Placebo of tolvaptan in Heart Failure, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 8 sites in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-10-22.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing tolvaptan in Heart Failure — none open to participants now, none under way, none of them phase 3. Tolvaptan · Heart Failure.
Among the 19 studies testing tolvaptan in Heart Failure, this one is the 8th largest by enrollment, is one of 2 that started in 2011, is one of 9 in phase 4, and was the 8th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →None of the 19 studies testing tolvaptan in Heart Failure is open now. The open studies under Heart Failure, anywhere →
Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 20 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 60 across the 19 interventional studies. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
17 studies in Heart Failure by Otsuka Holdings Co., Ltd.: none open now, 1 under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 17 studies in Heart Failure by Otsuka Holdings Co., Ltd., this one is the 8th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2011, is one of 2 in phase 4, and was the 7th registered.
Otsuka Holdings Co., Ltd.’s Heart Failure studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing tolvaptan in Heart Failure, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 17 in Heart Failure:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
One tolvaptan 15 mg tablet or placebo tablet will be orally administered once daily in the morning for up to 14 days to heart failure patients with volume overload that does not show adequate response to other diuretics such as loop diuretics in order to investigate the effect of tolvaptan on the mid- to long-term prognosis of the target population. The efficacy of tolvaptan during the treatment period will also be investigated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial due to any of the following conditions or symptoms:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
15 mg
Drug: Tolvaptan
Placebo
Drug: Placebo of tolvaptan
Once-daily oral administration of one tolvaptan 15 mg tablet in the morning
Once-daily oral administration of one placebo tablet in the morning
Cummulative Incidence of Events at Week 26
From start day of IMP administration to final day of follow up period, 1) and 2) below were defined as event 1. Death from cardiovascular events 2. Worsening of heart failure * The day of re-hospitalization due to worsening of heart failure * The day of medication below due to worsening of heart failure Phosphodiesterase III inhibitors (Injection), Catecholamine preparations (Injection), Colforsin preparations (Injection), Diuretics (Injection), Human atrial natriuretic peptide preparations (Injection):Calperitide (Injection)
Time frame: Week 26
Mortality (Number of Death)
Statistical comparison was not done.
Time frame: Week26
Body Weight
The comparison of the average of amount of change from baseline. Statistical comparison was not done.
Time frame: Day15
Number of Subjects Whose Lower Limb Edema Severity Grading Improved by One or More Grade
Of the subjects who had lower limb edema at baseline, the number of subjects whose lower limb edema severity grading. Statistical comparison was not done.
Time frame: Day15
Jugular Venous Distension
The comparison of the average of amount of change from baseline. Statistical comparison was not done.
Time frame: Day15
Change in Liver Size From Baseline
The comparison of the average of amount of change from baseline. Statistical comparison was not done.
Time frame: Day15
Pulmonary Rales
Of the subjects who had pulmonary rales at baseline, the number of subjects whose symptom was resolved at completion of treatment. Statistical comparison was not done.
Time frame: Day15
Third Heart Sound
Of the subjects who had third heart sound at baseline, the number of subjects whose symptom was resolved at completion of treatment. Statistical comparison was not done.
Time frame: Day15
Cardiothoracic Ratio
Investigator majored Thoracic length and Cardiac length from chest X-ray. Cardiothoracic Ratio was calculated from Cardiac length/Thoracic length\*100. Lowering of Cardiothoracic Ratio suggests recovery from heart congestion. The comparison of the average of amount of change from baseline. Statistical comparison was not done.
Time frame: Day15
Pulmonary Congestion
Of the subjects who had pulmonary congestion at baseline, the number of subjects whose pulmonary congestion severity grading showed an improvement of one grade or more (eg, moderate to mild) at completion of treatment. Statistical comparison was not done.
Time frame: Day15
Plasma Brain Natriuretic Peptide (BNP) Concentration
The comparison of the average of amount of change from baseline. Statistical comparison was not done.
Time frame: Day15
Dypnea
Of the subjects who had dyspnoea at baseline, the number of subjects whose symptom was resolved at completion of treatment. Statistical comparison was not done.
Time frame: Day15
Number of Subjects Whose New York Heart Association (NYHA) Classification Improved by One More Grade From Baseline
New York Heart Association (NYHA) Classification is below ClassI:No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). ClassII:Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). ClassIII:Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. ClassIV:Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.
Time frame: The day after last IMP administration and Baseline
| Milestone | Tolvaptan | Placebo |
|---|---|---|
| Started | 50 | 50 |
| Completed | 42 | 47 |
| Not completed | 8 | 3 |
| Withdrew: Physician decision | 5 | 3 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Deviation of exclusion criteria | 1 | 0 |
From start day of IMP administration to final day of follow up period, 1) and 2) below were defined as event 1. Death from cardiovascular events 2. Worsening of heart failure * The day of re-hospitalization due to worsening of heart failure * The day of medication below due to worsening of heart failure Phosphodiesterase III inhibitors (Injection), Catecholamine preparations (Injection), Colforsin preparations (Injection), Diuretics (Injection), Human atrial natriuretic peptide preparations (Injection):Calperitide (Injection)
| Percentage of events at 26 weeks | Tolvaptan | Placebo |
|---|---|---|
| Cummulative Incidence of Events at Week 26 | 35.6 | 43.8 |
Statistical comparison was not done.
| participants | Tolvaptan | Placebo |
|---|---|---|
| Mortality (Number of Death) | 2 | 3 |
The comparison of the average of amount of change from baseline. Statistical comparison was not done.
| kg | Tolvaptan | Placebo |
|---|---|---|
| Body Weight | -1.99 ± 1.61 | -1.20 ± 1.97 |
Of the subjects who had lower limb edema at baseline, the number of subjects whose lower limb edema severity grading. Statistical comparison was not done.
| participants | Tolvaptan | Placebo |
|---|---|---|
| Number of Subjects Whose Lower Limb Edema Severity Grading Improved by One or More Grade | 27 | 16 |
The comparison of the average of amount of change from baseline. Statistical comparison was not done.
| cm | Tolvaptan | Placebo |
|---|---|---|
| Jugular Venous Distension | -0.94 ± 2.07 | -1.23 ± 2.78 |
The comparison of the average of amount of change from baseline. Statistical comparison was not done.
| cm | Tolvaptan | Placebo |
|---|---|---|
| Change in Liver Size From Baseline | -0.20 ± 0.52 | -0.19 ± 0.55 |
Of the subjects who had pulmonary rales at baseline, the number of subjects whose symptom was resolved at completion of treatment. Statistical comparison was not done.
| participants | Tolvaptan | Placebo |
|---|---|---|
| Pulmonary Rales | 13 | 9 |
Of the subjects who had third heart sound at baseline, the number of subjects whose symptom was resolved at completion of treatment. Statistical comparison was not done.
| participants | Tolvaptan | Placebo |
|---|---|---|
| Third Heart Sound | 8 | 10 |
Investigator majored Thoracic length and Cardiac length from chest X-ray. Cardiothoracic Ratio was calculated from Cardiac length/Thoracic length\*100. Lowering of Cardiothoracic Ratio suggests recovery from heart congestion. The comparison of the average of amount of change from baseline. Statistical comparison was not done.
| Percentage | Tolvaptan | Placebo |
|---|---|---|
| Cardiothoracic Ratio | -2.13 ± 3.53 | -0.83 ± 3.85 |
Of the subjects who had pulmonary congestion at baseline, the number of subjects whose pulmonary congestion severity grading showed an improvement of one grade or more (eg, moderate to mild) at completion of treatment. Statistical comparison was not done.
| participants | Tolvaptan | Placebo |
|---|---|---|
| Pulmonary Congestion | 24 | 20 |
The comparison of the average of amount of change from baseline. Statistical comparison was not done.
| pg/mL | Tolvaptan | Placebo |
|---|---|---|
| Plasma Brain Natriuretic Peptide (BNP) Concentration | -72.60 ± 268.90 | -166.96 ± 353.34 |
Of the subjects who had dyspnoea at baseline, the number of subjects whose symptom was resolved at completion of treatment. Statistical comparison was not done.
| participants | Tolvaptan | Placebo |
|---|---|---|
| Dypnea | 11 | 12 |
New York Heart Association (NYHA) Classification is below ClassI:No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). ClassII:Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). ClassIII:Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. ClassIV:Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.
| participants | Tolvaptan | Placebo |
|---|---|---|
| Number of Subjects Whose New York Heart Association (NYHA) Classification Improved by One More Grade From Baseline | 22 | 24 |
Collected over 26 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tolvaptan | — | 24/50 (48%) | 31/50 (62%) |
| Placebo | — | 22/50 (44%) | 7/50 (14%) |
| Event | Tolvaptan | Placebo |
|---|---|---|
| Cardiac failureCardiac disorders | 13/50 | 19/50 |
| Acute Cardiac FailureCardiac disorders | 0/50 | 1/50 |
| Congestive Cardiac FailureCardiac disorders | 1/50 | 0/50 |
| Ventricular TachycardiaCardiac disorders | 0/50 | 1/50 |
| CataractEye disorders | 1/50 | 0/50 |
| Diabetic retina edemaEye disorders | 1/50 | 0/50 |
| Inguinal herniaGastrointestinal disorders | 1/50 | 0/50 |
| NauseaGastrointestinal disorders | 1/50 | 0/50 |
| Large intestine polypGastrointestinal disorders | 1/50 | 0/50 |
| FeverGeneral disorders | 1/50 | 0/50 |
| Event | Tolvaptan | Placebo |
|---|---|---|
| ThirstGeneral disorders | 10/50 | 1/50 |
| Blood sodium increasedInvestigations | 8/50 | 0/50 |
| ConstipationGastrointestinal disorders | 6/50 | 2/50 |
| ContusionInjury, poisoning and procedural complications | 1/50 | 3/50 |
| Blood potassium increasedInvestigations | 3/50 | 1/50 |
| HypokalaemiaMetabolism and nutrition disorders | 3/50 | 0/50 |
| Age, Categorical(Participants) | Tolvaptan | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 9 | 13 | 22 |
| >=65 years | 41 | 37 | 78 |
| Age, Continuous(years) | Tolvaptan | Placebo | Total |
|---|---|---|---|
| Mean | 73.8 ± 8.4 | 71.7 ± 11.2 | 72.8 ± 9.9 |
| Sex: Female, Male(Participants) | Tolvaptan | Placebo | Total |
|---|---|---|---|
| Female | 21 | 13 | 34 |
| Male | 29 | 37 | 66 |
| Region of Enrollment(participants) | Tolvaptan | Placebo | Total |
|---|---|---|---|
| Japan | 50 | 50 | 100 |
The record gives a start of Sep 2011, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2019, 5 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Otsuka Pharmaceutical Co., Ltd. →